Cardiac Troponin I monitoring pilot study

• Research type

  Research Study

• Full title

  Cardiac troponin I monitoring in breast cancer patients receiving anthracycline or trastuzumab therapy: a pilot study

• IRAS ID

  192417

• Contact name

  Peter Henriksen

• Contact email

  phenrik1@exseed.ed.ac.uk

• Sponsor organisation

  NHS Lothian

• Duration of Study in the UK

  3 years, 5 months, 16 days

• Research summary

  In a small number of patients being treated for breast cancer the chemotherapy treatment they receive can damage their heart and can lead to a condition called heart muscle failure. This causes the heart muscle to deliver less blood to the rest of the body and can make the patient breathless. We are developing a method to monitor injury to heart muscle so that cancer treatments can be changed and further heart muscle injury can be avoided.

  In this study we will examine a blood test called cardiac troponin I which can detect very slight heart muscle injury. We will look at the levels of cardiac troponin I in blood and monitor how the levels change throughout breast cancer treatment (specifically anthracycline and/or trastuzumab therapy).
  The blood sample taken for cardiac troponin I measurement will be collected by the GP surgery or in the oncology clinic.

• REC name

  London - Surrey Research Ethics Committee

• REC reference

  15/LO/1968

• Date of REC Opinion

  6 Nov 2015

• REC opinion

  Favourable Opinion